NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00826644,Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient,https://clinicaltrials.gov/study/NCT00826644,COMBAT,COMPLETED,"Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin derivative, that exhibits anticancer effects by inhibiting topoisomerase I. The investigators will have a randomized prospective multicenter trial of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung cancer.

Primary endpoints

* to assess Response Rate

Secondary endpoints

* to assess Overall response duration, Time to progression, Overall survival",NO,"Carcinoma, Small Cell",DRUG: Belotecan|DRUG: Etoposide|DRUG: Cisplatin,"To assess the response Rate of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung cancer, two years","to assess the overall response duration, two years|To assess the time to progression, two years|to assess the overall survival, two years",,Chonnam National University Hospital,Chong Kun Dang Pharmaceutical,ALL,"ADULT, OLDER_ADULT",PHASE3,147,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CSCLC-0810,2009-01,2013-02,2013-02,2009-01-22,,2021-08-09,"Chonnam National University Hwasun Hospital, Hwasun, 58128, Korea, Republic of",
